Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs).
Latest news
05 Oct, 2020
Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital
16 Sep, 2020
Pneumagen Announces Scientific Advisory Board and Development Team Appointments
27 May, 2020
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
Meet the team
Douglas Thomson
Chief Executive Officer
Dr David Howat
Development Director
Thomas Engelen
Non-executive Chairman
Professor Garry Taylor
Director and Chairman of the Scientific Advisory Board